Statistics from Altmetric.com
We read the article by Bhardwaj and coworkers1 with great interest. With their elegantly designed, randomised, single-blind, placebo-controlled study, Dr. Sarin and his research group have turned over a new leaf in the controversy on the effectiveness of non-selective beta blockers (NSBBs) in preventing the progression from small to large varices in patients who have not bled (table 1).
Carvedilol has been shown to be more potent in decreasing portal pressure due to its additional anti-α1-adrenergic activity,2 and thus, achieves hemodynamic response even in non-responders to propranolol.3 Based on the stage-dependent pathophysiology of portal hypertension (PH), the anti-α1-mediated decrease in intrahepatic resistance might be particularly beneficial in patients with less pronounced clinically significant PH, when intrahepatic resistance is still a major determinant of portal …
Collaborators Vienna Hepatic Hemodynamic Lab (MM, MP-R and TR).
Contributors MM performed the meta-analysis. MM, MP-R and TR drafted and revised the manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.